Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study
Authors:
- Alejandro HobermanAHAlejandro Hoberman
- Peter SilasPSPeter Silas
- Rosa PratoRPRosa Prato
- Samantha BosisSBSamantha Bosis
- Judith M. MartinJMJudith M. Martin
- Isabelle LechevinILIsabelle Lechevin
- Mariapia PossidenteMPMariapia Possidente
- Sara ManzellaSMSara Manzella
- Luca MoraschiniLMLuca Moraschini
- Maria LattanziMLMaria Lattanzi
- Pavitra KeshavanPKPavitra Keshavan
Open Access
- 9 June 2026
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2683201
Abstract
Meningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16–18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16–18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.Keywords
Funding Information
- GlaxoSmithKline
This publication has 26 references indexed in Scilit:
- Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trialVaccine, 2018
- Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccinationHuman Vaccines & Immunotherapeutics, 2018
- Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency studyVaccine, 2015
- A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trialVaccine, 2015
- Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescentsHuman Vaccines & Immunotherapeutics, 2015
- Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in AdolescentsThe Journal of Pediatrics, 2014
- A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development ProgramDrugs, 2013
- Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccinesVaccine, 2013
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigensVaccine, 2012
- Menveo®: a novel quadrivalent meningococcal CRM197conjugate vaccine against serogroups A, C, W-135 and YExpert Review of Vaccines, 2011